Wall Street Zen Downgrades Microbot Medical (NASDAQ:MBOT) to Sell

Microbot Medical (NASDAQ:MBOT) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other research analysts also recently issued reports on MBOT. Zacks Research downgraded Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $12.00.

Microbot Medical Price Performance

Microbot Medical stock opened at $2.42 on Friday. The business has a 50 day moving average of $3.33 and a 200-day moving average of $2.83. Microbot Medical has a 1 year low of $0.89 and a 1 year high of $4.67. The company has a market capitalization of $162.53 million, a P/E ratio of -4.17 and a beta of 1.25.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Equities analysts anticipate that Microbot Medical will post -0.71 EPS for the current year.

Institutional Trading of Microbot Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MBOT. U.S. Capital Wealth Advisors LLC acquired a new stake in Microbot Medical during the 2nd quarter valued at approximately $25,000. American Century Companies Inc. acquired a new stake in Microbot Medical during the second quarter worth approximately $32,000. SLT Holdings LLC acquired a new stake in Microbot Medical during the third quarter worth approximately $38,000. Beacon Capital Management LLC grew its position in shares of Microbot Medical by 166.7% during the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company’s stock worth $40,000 after buying an additional 10,000 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Microbot Medical during the 1st quarter worth approximately $42,000. Institutional investors and hedge funds own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.